Moderna, Inc. (NASDAQ:MRNA - Get Free Report) shares were down 3.6% on Monday. The company traded as low as $212.50 and last traded at $215.27. Approximately 6,997,765 shares were traded during mid-day trading, a decline of 44% from the average session volume of 12,547,155 shares. The stock had previously closed at $223.37.
Wall Street Analyst Weigh In
MRNA has been the subject of several recent research reports. Weiss Ratings reissued a "sell (d-)" rating on shares of Moderna in a research report on Wednesday, September 9th. Singular Research upgraded Moderna to a "hold" rating in a research note on Wednesday, September 23rd. Brookline Capital Markets reiterated a "buy" rating on shares of Moderna in a research note on Wednesday, August 19th. Morgan Stanley boosted their target price on Moderna from $89.00 to $95.00 and gave the stock an "equal weight" rating in a research note on Wednesday, October 7th. Finally, William Blair downgraded Moderna from an "outperform" rating to a "market perform" rating in a report on Tuesday, October 27th. Six analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and four have assigned a Sell rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $113.75.
Check Out Our Latest Report on MRNA
Moderna Stock Performance
The company has a current ratio of 3.62, a quick ratio of 3.47 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $87.10 billion, a price-to-earnings ratio of -30.32 and a beta of 1.16. The stock's 50 day moving average price is $201.67 and its two-hundred day moving average price is $96.41.
Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating the consensus estimate of ($1.10) by $1.48. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $890.25 million. Moderna had a negative net margin of 110.46% and a negative return on equity of 25.79%. The firm's revenue for the quarter was up 29.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.51) EPS. On average, analysts forecast that Moderna, Inc. will post -5.14 EPS for the current year.
Insider Activity
In other news, President Stephen Hoge sold 39,145 shares of the firm's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $220.72, for a total transaction of $8,640,084.40. Following the completion of the sale, the president directly owned 1,636,565 shares of the company's stock, valued at $361,222,626.80. This trade represents a 2.34% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the business's stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares in the company, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 197,251 shares of company stock worth $33,875,904. Insiders own 10.80% of the company's stock.
Institutional Inflows and Outflows
A number of hedge funds have recently bought and sold shares of MRNA. State of Tennessee Department of Treasury lifted its position in Moderna by 21.7% during the 3rd quarter. State of Tennessee Department of Treasury now owns 82,511 shares of the company's stock worth $15,889,000 after buying an additional 14,689 shares in the last quarter. Bank OZK bought a new position in Moderna during the third quarter worth $1,775,000. Empirical Finance LLC boosted its holdings in shares of Moderna by 3.6% during the 3rd quarter. Empirical Finance LLC now owns 9,767 shares of the company's stock worth $1,881,000 after buying an additional 341 shares in the last quarter. Entropy Technologies LP bought a new stake in Moderna in the third quarter valued at $480,000. Finally, Jump Financial LLC grew its position in Moderna by 470.7% during the third quarter. Jump Financial LLC now owns 154,274 shares of the company's stock valued at $29,709,000 after buying an additional 127,243 shares during the period. 75.33% of the stock is currently owned by institutional investors.
Moderna Company Profile
(
Get Free Report)
Moderna, Inc. is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease. The company's commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases. Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Moderna, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Moderna wasn't on the list.
While Moderna currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.